Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment

Bristol-Myers Squibb232 enrolled

Overview

The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.

Study Type

OBSERVATIONAL

Enrollment

232

Conditions

Psoriasis

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of moderate-to-severe Psoriasis (PsO) by physician (phase 1) or self-reported (phase 2) * Currently taking systemic psoriasis treatment * Japanese resident aged 20 years and older Exclusion Criteria: * Unable or unwilling to provide informed consent * Diagnosis of guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis

Locations (1)

Local Institution

Morrisville, North Carolina, United States

Outcomes

Primary Outcomes

Psoriasis (PsO) patient preferences of moderate-to-severe systemic treatment atrribute

Time frame: Within 60 minutes of survey/interview

Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 1: Sex

Time frame: At Baseline

Distribution of socio-demographic characteristics of PsO participants in Phase 1: Age

Time frame: At Baseline

Distribution of clinical characteristics of PsO participants in Phase 1: Time since PsO diagnosis

Time frame: At Baseline

Distribution of clinical characteristics of PsO participants in Phase 1: Severity of PsO

Time frame: At Baseline

Distribution of clinical characteristics of PsO participants in Phase 1: Current treatments for PsO

Time frame: At Baseline

Distribution of clinical characteristics of PsO participants in Phase 1: Time on current PsO treatment

Time frame: At Baseline

Distribution of socio-demographic characteristics of PsO participants in Phase 1: Residence

Time frame: At Baseline

Distribution of socio-demographic characteristics of PsO participants in Phase 1: Employment status

Time frame: At Baseline

Distribution of socio-demographic characteristics of PsO participants in Phase 1: Education

Time frame: At Baseline

Distribution of clinical characteristics of PsO participants in Phase 1: Total number of previous treatments

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Time frame: At Baseline

Distribution of clinical characteristics of PsO participants in Phase 1: Previous treatments for PsO

Time frame: At Baseline

Distribution of socio-demographic characteristics of PsO participants in Phase 1: Level of income

Time frame: At Baseline

Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Sex

Time frame: At Baseline

Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Age

Time frame: At Baseline

Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Height

Time frame: At Baseline

Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Weight

Time frame: At Baseline

Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Residence

Time frame: At Baseline

Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Employment status

Time frame: At Baseline

Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Type of occupation

Time frame: At Baseline

Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Education

Time frame: At Baseline

Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time since PsO diagnosis

Time frame: At Baseline

Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Self-reported severity

Time frame: At Baseline

Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Current treatments for PsO

Time frame: At Baseline

Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time on current PsO treatment

Time frame: At Baseline

Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Previous treatments for PsO

Time frame: At Baseline

Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Comorbid conditions of interest

Time frame: At Baseline

Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Level of income

Time frame: At Baseline